Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Intelligence

Set Alert for Market Intelligence

Behind The Blockbuster: Investors Sound Off On Biogen's Future With Spinraza

Entering 2017 with freshly approved Spinraza and new CEO Michel Vounatsos, Biogen still faces challenges and uncertainty. A poll of investors highlights expectations for the company.

Business Strategies Commercial Neurology
Advertisement

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV

While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.

Business Strategies Commercial

AZ’s ZS-9 Targets Hyperkalemia Sector As It Nears EU Market

A potential near-blockbuster drug, AstraZeneca’s Lokelma (ZS-9), has received a positive opinion from Europe’s CHMP and, if approved, will soon have to justify best-in-class plaudits and a hefty acquisition price.

Approvals Market Intelligence

Pharma's Orphan Drug Activity, An Infographic

More than two-fifths of new drugs approved in the US last year were orphan drugs, and there are more than 4,500 drugs in active development for rare diseases. Effective orphan drug legislation and incentivization programs introduced gradually around the world since the 1980s mean rare diseases are no longer a rare sighting in the pharma industry pipeline, as this infographic illustrates.

Rare Diseases Market Intelligence

How Will Pharma M&A Change In 2017?

Industry consultants survey the landscape for pharma deal making in 2017. More deals, higher prices and asset swaps as repatriated cash burns holes in US pharma's pockets are just for starters.

Deals Market Intelligence

Five Big Picture R&D Questions For J&J’s Stoffels, Novartis’s Narasimhan

J&J’s chief scientific officer, Dr. Paul Stoffels, and Novartis’ global head of drug development and chief medical officer, Dr. Vasant Narasimhan, were both among the global industry attendees at the recent BioAsia 2017 meeting in Hyderabad. They shared with Scrip their big picture perspectives on a range of key talking points around R&D, including the cost conundrum and the next big things in the world of medicine.

Research and Development Strategies Market Intelligence

COMPASS Success Reinforces J&J/Bayer's Broad Labeling Strategy For Xarelto

J&J will be talking to FDA regarding expanded approval for peripheral arterial disease and coronary artery disease following early stop of COMPASS outcomes study; strong data will be needed if asymptomatic patients are targeted.

Clinical Trials Research and Development Strategies
See All
UsernamePublicRestriction

Register